Analytical Data
-
Gene name
S100A9
- Application
-
Alternative Names
MRP14; MIF; 60B8AG; CFAG; NIF; CAGB; CGLB; L1AG; P14; Calgranulin B; Migration inhibitory factor-related protein 14; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P31725
-
Expression Region
Met1~Lys113
-
Molecular Weight
15&30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
S100A9, a member of the S100 protein family, is a calcium-binding protein that plays crucial roles in various biological processes, including inflammation, cell growth, and differentiation. Its expression is notably elevated in inflammatory conditions and various tumors, making it a potential biomarker for diseases like rheumatoid arthritis, cancer, and cardiovascular disorders. Research has shown that S100A9 participates in the regulation of immune responses by modulating the activity of immune cells, particularly neutrophils and monocytes. Additionally, it has been implicated in the formation of the S100A8/S100A9 complex, which exhibits pro-inflammatory properties and influences the tumor microenvironment. Given its significant involvement in pathophysiological conditions, S100A9 recombinant protein has gained attention as a research tool for studying its functional roles and therapeutic potential. The recombinant production of S100A9 allows for the investigation of its biological activities in vitro and in vivo, facilitating the exploration of targeted therapies aimed at mitigating inflammatory responses and tumor progression. Understanding the mechanisms by which S100A9 operates may lead to novel therapeutic strategies and enhance our knowledge of its implications in health and disease. Thus, ongoing research into S100A9 recombinant protein is vital for elucidating its functions and developing advanced diagnostic and therapeutic modalities.
